Table 2 Association of B7-H3 expression with clinicopathological data and with CD276 mRNA
B7-H3 expression | |||||
|---|---|---|---|---|---|
Parameter | n (%) | Low/Moderate | High | p | |
Gender | |||||
Male | 26 (63.4) | 20 (69) | 6 (50) | 0.251 | |
Female | 15 (36.6) | 9 (31) | 6 (50) | ||
Age group | |||||
Infant | 5 (12.2) | 4 (13.8) | 1 (8.3) | 0.416 | |
Child | 17 (41.5) | 14 (48.3) | 3 (25) | ||
Adolescent | 5 (12.2) | 3 (10.3) | 2 (16.7) | ||
Adult | 14 (34.1) | 8 (27.6) | 6 (50) | ||
Molecular subgroup | |||||
WNT | 6 (14.6) | 4 (13.8) | 2 (16.7) | 0.506 | |
SHH | 19 (46.3) | 12 (41.4) | 7 (58.3) | ||
Group 3 | 4 (9.8) | 4 (13.8) | 0 (0) | ||
Group 4 | 12 (29.3) | 9 (31) | 3 (25) | ||
Histology | |||||
Anaplastic/large cells | 2 (4.9) | 2 (6.9) | 0 (0) | 0.486 | |
Classic | 28 (68.3) | 19 (65.5) | 9 (75) | ||
Extensive nodularity | 3 (7.3) | 3 (10.3) | 0 (0) | ||
Nodular/desmoplastic | 8 (19.5) | 5 (17.2) | 3 (25) | ||
Surgical resection | |||||
Partial | 18 (43.9) | 12 (41.4) | 6 (50) | 0.613 | |
Total | 23 (56.1) | 17 (58.6) | 6 (50) | ||
Metastasis at diagnosis | |||||
Absent | 32 (78) | 25 (86.2) | 7 (58.3) | 0.050 | |
Present | 9 (22) | 4 (13.8) | 5 (41.7) | ||
TERTstatus | |||||
WT | 14 (60.9) | 8 (57.1) | 6 (66.7) | 0.648 | |
Mutated | 9 (39.1) | 6 (42.9) | 3 (33.3) | ||
B7-H3 cellular localization | |||||
Cytoplasm | 26 (66.7) | 19 (70.4) | 7 (58.3) | 0.462 | |
Cytoplasm/membranous | 13 (33.3) | 8 (29.6) | 5 (41.7) | ||
Survival time | |||||
Median (95% CI) | 41 (100) | - | 83.7 (3.9–163.5) | 0.09 | |
CD276mRNA counts | |||||
Mean ± SEM | 41 (100) | 444.5 ± 27.7 | 561.4 ± 42.2 | 0.027 | |
Parameters | Pearson correlation | p | |||
CD276mRNA counts vs. B7-H3 score | 0.336 | 0.032 | |||